Clinical Trials Logo

B-Cell Lymphomas clinical trials

View clinical trials related to B-Cell Lymphomas.

Filter by:

NCT ID: NCT05773040 Active, not recruiting - Lymphomas Clinical Trials

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Start date: April 14, 2023
Phase: Phase 1
Study type: Interventional

To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.

NCT ID: NCT05160064 Withdrawn - B-Cell Lymphomas Clinical Trials

Long-term Registry of Patients Treated With Loncastuximab Tesirine

Start date: June 30, 2022
Phase:
Study type: Observational [Patient Registry]

Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.

NCT ID: NCT03920631 Withdrawn - B Cell Lymphomas Clinical Trials

Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

MicroBLITZ
Start date: July 10, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out if microtransplantation (MST) in combination with nivolumab is safe and effective in patients with relapsed or refractory B cell lymphomas.

NCT ID: NCT03218072 Completed - B-cell Lymphomas Clinical Trials

A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

Start date: May 4, 2014
Phase: Phase 1
Study type: Interventional

To evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a potential rituximab biosimilar) in patients with CD20-positive B-cell lymphomas.

NCT ID: NCT02891590 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

Start date: September 2016
Phase: Phase 1
Study type: Interventional

The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma. The Secondary Objective is to evaluate the pharmacokinetics of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.

NCT ID: NCT02840110 Terminated - Multiple Myeloma Clinical Trials

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Start date: October 2016
Phase:
Study type: Observational

Subjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use, named patient Investigational New Drug application, expanded access program, or equivalent setting. No investigational product or treatment will be administered in this study. These subjects will be followed for safety monitoring on a schedule of decreasing frequency through 15 years post-ACTR treatment, in accordance with US FDA Regulatory guidance pertaining to long-term safety follow-up for study subjects receiving recombinant DNA-containing investigational products.

NCT ID: NCT02650414 Recruiting - B Cell Lymphomas Clinical Trials

CD22 Redirected Autologous T Cells for ALL

Start date: January 13, 2016
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART22" cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

NCT ID: NCT02247609 Recruiting - B-cell Lymphomas Clinical Trials

Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas

4SCAR19273
Start date: January 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Currently, a majority of B cell lymphomas cannot be cured by standard chemo-radiotherapy. Most B cell lymphomas express cluster of differentiation antigen 19 (CD19), which represents a very attractive target for chimeric antigen receptor (CAR)-based immune cell therapy. This study will evaluate a novel 4th generation CD19 CAR engineered with a self-withdrawal mechanism (19273-4SCAR) for both efficacy and safety in lymphoma patients.

NCT ID: NCT01955668 Completed - B Cell Lymphomas Clinical Trials

AZD6738 First Time in Patient Multiple Ascending Dose Study

Start date: November 2013
Phase: Phase 1
Study type: Interventional

In Part A to investigate the safety and tolerability of AZD6738 when given orally to patients with relapsed/refractory CLL, PLL or B cell lymphoma. In Part B to investigate the safety and tolerability of AZD6738 when given orally to patients with prospectively identified 11q deleted or ATM deficient, relapsed/refractory CLL

NCT ID: NCT01744912 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Start date: November 21, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether ublituximab in combination with lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies who have relapsed or are refractory after CD20 directed antibody therapy.